It’s thought to serve as an NMDA receptor antagonist, though research is now restricted.
The roots of 2F-DCK are not well-documented. It seems to have become available for sale on the online research compound marketplace in 2017, where it had been marketed as a legal replacement for ketamine. It was released following the successful introduction of a similar ketamine analog, deschloroketamine.
Subjective effects include sedation, engine control reduction, pain relief, internal hallucinations, conceptual thinking, euphoria, and dissociation. Dissociation is a intricate mental state characterized by perceptual distortions and feelings of detachment in the surroundings and one’s self. 2F-DCK’s effects are reported to be like those of ketamine. Much like ketamine, 2F-DCK’s effects are tremendously dose-dependent, with lesser doses producing alcohol-like intoxication and higher doses producing hallucinogenic out-of-body states (also called a”k-hole“).
2-Fluorodeschloroketamine, or 2-(2-Fluorophenyl)-2-methylamino-cyclohexanone, is classed as an arylcyclohexylamine drug. Arylcyclohexylamines medications are named for their structures, including a cyclohexane ring bound into an aromatic ring alongside an amine group. 2-FDCK includes a phenyl ring secured to a cyclohexane ring replaced with a ketone group (cyclohexanone). An amino methyl series (-N-CH3) is bound into the adjacent alpha carbon (R2) of this cyclohexanone ring. Additionally, the phenyl ring is replaced in R2 using a fluorine group.
2-Fluorodescholoroketamine is a chiral molecule and is often created as a racemate. Des- is a prefix used in chemistry to denote the lack of a functional group (in this case”chloro”) hence 2-FDCK is known for comprising a fluorine substitution at its phenyl ring rather than the contamination that’s found in ketamine.
On account of the lack of research regarding the material, all debate regarding the pharmacology of it’s purely based on its own structure and subjective effect similarities to other arylcyclohexylamine dissociatives like DCK and ketamine. Bearing this in mind, 2-Fluorodeschloroketamine is considered to act as an NMDA receptor antagonist.
NMDA receptors to allow for electrical signals to pass between neurons in the brain and spinal column; to the signs to maneuver, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons contributes to loss of feeling, difficulty moving, and eventually this material’s equivalent of the”K-hole.”